Ciphergen and MD Anderson Cancer Center Sign Ovarian Cancer Biomarker Alliance
Ciphergen Diagnostics, a division of Ciphergen Biosystems, has signed a research and license agreement with the University of Texas MD Anderson Cancer Center to discover ovarian cancer biomarkers, the company said this week.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.